Tirzepatide is the active ingredient in Zepbound, approved by the Food and Drug Administration (FDA) specifically for weight loss. Semaglutide was initially approved under the brand name Ozempic ...

Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action.

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

The retrospective study involved reviewing the medical charts of 100 adults with T1D, 50 who were prescribed semaglutide and 50 who were prescribed tirzepatide. The majority (84% of those ...

Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...

Tirzepatide and semaglutide, while effective, are not cost-effective due to high prices, negating healthcare savings. Combining antiobesity medications with lifestyle modification improves health ...

Current Status of GLP-1 Medications The FDA has officially determined that the shortage of both semaglutide and tirzepatide injection products is now resolved. Semaglutide: The FDA determined on ...

Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Semaglutide has been shown to reduce the risk of complications in patients with chronic kidney disease, an indication for which it has been filed for approval, while tirzepatide has been shown to ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.